abstract |
Use of a polypeptide comprising an area of at least 150 amino acids that has at least 80% sequence identity with the corresponding zone of amino acids 1 to 259 of a mature, natural and human apoE, in which the polypeptide does not comprises residues 260 to 299 of the carboxyl terminal of said apoE, for the preparation of a pharmaceutical composition intended to reduce cholesterol, retarding the onset of atherosclerosis, or treating atherosclerosis in a mammal without inducing hypertriglyceridemia, in which said polypeptide must administered to said mammal and said polypeptide, and when administered or expressed in a mammal, it is capable of reducing the level of total cholesterol in the serum without inducing hypertriglyceridemia. |